Technical analysis of Cyclerion Therapeutics, Inc. (CYCN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier.
Price Performance
| 1 month | +9.60% |
| 3 months | +41.12% |
| Year-to-date | +255.57% |
| 1 year | +93.81% |
| 3 years | +15.79% |
| 5 years | -92.76% |
52-Week Range
| 52-week High | $59.36 |
| 52-week Low | $7.21 |
| Avg Volume (90d) | 17K |
Technical Indicators
| SMA 50 | $26.63 |
| SMA 200 | $18.29 |
| Beta | 0.89 |
| 30-day Volatility (annualised) | 134.5% |
| Price vs SMA 50 | +18.7% |
| Price vs SMA 200 | +72.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $13.09 | |
| 2025-11 | $11.06 | -15.5% |
| 2025-12 | $8.89 | -19.6% |
| 2026-01 | $9.52 | +7.1% |
| 2026-02 | $9.45 | -0.7% |
| 2026-03 | $10.85 | +14.8% |
| 2026-04 | $23.17 | +113.5% |
| 2026-05 | $22.05 | -4.8% |
| 2026-06 | $23.73 | +7.6% |
| 2026-07 | $24.08 | +1.5% |
| 2026-08 | $25.76 | +7.0% |
| 2026-09 | $31.61 | +22.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $23.52 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.81 |
| EV / EBITDA | -2.14 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 0.82 |